Floatz logo

cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine

HER2 Negative Breast Carcinoma

University of WashingtonvaccinePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

191 Active assets in the HER2 Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine is also rated in:

breast cancerDormant
B
Indicative ·
58 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →